US Bancorp DE Has $11.42 Million Position in Novo Nordisk A/S $NVO

Key Points

• US Bancorp DE trimmed its stake in Novo Nordisk by 16.7% in Q4, selling 44,950 shares and now holding 224,413 shares worth about $11.42 million per its latest SEC filing.
• Novo Nordisk posted a quarterly earnings beat with $1.01 EPS vs. $0.90 expected and $12.43 billion in revenue, reported strong margins (net margin 33.03%, ROE 68.91%), and paid a $1.2751 dividend on April 8.
• Near-term catalysts include the U.S. launch of oral Ozempic and FDA moves limiting GLP‑1 compounding, which could support pricing, but rising generic semaglutide approvals and stronger competition from Eli Lilly are increasing pressure; analysts hold a consensus rating of Hold with an average target of about $65.56.

US Bancorp DE lowered its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 224,413 shares of the company's stock after selling 44,950 shares during the quarter. US Bancorp DE's holdings in Novo Nordisk A/S were worth $11,419,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NVO. Smith Chas P & Associates PA Cpas lifted its position in Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock valued at $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC lifted its position in Novo Nordisk A/S by 13.7% in the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock valued at $17,267,000 after acquiring an additional 37,453 shares in the last quarter. Markel Group Inc. lifted its position in Novo Nordisk A/S by 4.9% in the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock valued at $131,436,000 after acquiring an additional 110,061 shares in the last quarter. WCM Investment Management LLC lifted its position in Novo Nordisk A/S by 3.7% in the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company's stock valued at $151,636,000 after acquiring an additional 97,477 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $3,171,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 3.8%

NYSE:NVO opened at $43.84 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $195.76 billion, a price-to-earnings ratio of 12.64, a price-to-earnings-growth ratio of 10.42 and a beta of 0.77. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The firm has a 50-day moving average price of $38.50 and a two-hundred day moving average price of $47.26.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts expect that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were issued a $1.2751 dividend. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S's payout ratio is 50.43%.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. TD Cowen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Weiss Ratings cut shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, April 22nd. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly's Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.